GLP-1s are not going anywhere pharma manufacturers continue to evolve their GLP-1/GIP product offerings (e.g., Eli Lillys Zepbound is the newest on the market), and the number of addressable indications is increasing (e.g., recent clinical evidence that may merit further FDA approval of GLP-1s for cardio-metabolic, nephrological and neurological indications)
Experiment 1 : Cells were treated with increasing concentrations of FFAs (0.25, 0.5, and 1.0 mM), lipopolysaccharides or tumor necrosis factor- for 24 h or were treated with FFAs (0.5 mM) at different times (12, 24, 36, and 48 h)
doi: 10.3389/fped.2023.1212405 Received 26 April 2023 Accepted 03 July 2023 Published 27 July 2023 Volume 11 - 2023 Edited by Massimo Zeviani, University of Padua, Italy Reviewed by Carlo Fiore Viscomi, University of Padua, Italy Muhammad Ikram Ullah, Jouf University, Saudi Arabia Updates Copyright 2023 Wu, Jiao, Xia, Yan, Liu, Cao and Ma
Bioequivalence ensures similar safety, strength, dosage form, and effectiveness
